OIS@AAO 2016 Videos

Encore Vision’s EV06 ophthalmic solution (lipoic acid choline ester 1.5%) is “a prodrug that metabolizes into choline and lipoid acid, two naturally occurring substances,” that…

Mynosys has developed the means to create “an ideal capsulotomy,” in its ZEPTO device, said John Hendrick, president and chief executive officer. The ZEPTO is…

Novaliq has been transforming how clinicians think about artificial tears since the company’s inception, said Bernhard Günther, co-founder and chief executive officer. NovaTears/EvoTears is a…

PowerVision’s fluid-controlled accommodating intraocular lens (IOL) is “the first true shape-changing lens that mimics the eye’s natural accommodative process,” said co-founder, president, and chief executive…

Shelley Boyd, MD, president and CEO of Tracery Ophthalmics Inc., introduced the company’s clinical-stage “functional ophthalmic imaging platform” to OIS@AAO. The company – funded by…

  Top-line Phase IIb results showed Allegro Ophthalmics’ first-in-class integrin peptide inhibitor, Luminate, achieved its primary and secondary endpoints for efficacy and safety in treatment…

“This is not your father’s steroid,” Alimera Sciences’ CEO Dan Myers told the Posterior Segment Company Showcase at OIS@AAO 2016 in discussing new evidence that…

CHICAGO—pSivida has created a business model to solely concentrate on preventing blindness through proprietary sustained-release drug technologies, said newly appointed president and CEO Nancy Lurker.…

CHICAGO—Aerie’s CEO and chairman, Vincent Anido, Jr., PhD, has said the company’s goal is to become a major ophthalmic pharmaceutical firm by using Rho-kinase inhibitors…

Gavin Herbert, founder, Allergan, took over the company when he was in his mid-20s, and he built an industry leader by hiring the right people…

The principals of LacriScience – Paul T. Gavaris, MD, managing member and CEO, LacriScience, Chris D. Geddes, PhD, chief biomedical and Ali Ghovanlou,plasmonics consultant– deliver…

David Pyott, former CEO, Allergan, doesn’t mince words. He explains why he took such an aggressive stance against Valeant’s bid to buy his former company.…